Compare DexCom, Inc. (DXCM) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Fubotv Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Fubotv Inc trades at $8.86 (market cap $1.02B). The key difference: DexCom, Inc. is far larger — about 31.2× Fubotv Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Fubotv Inc for 35 Days on average.
| DXCM | FUBO | |
|---|---|---|
Market Cap | $31.86B | $1.02B |
Volume | 3,607,070 | 978,631 |
Sector | Health | Media |
52-Week High | $92.34 | $48.96 |
52-Week Low | $54.84 | $8.09 |
Typical Hold Time | 62 Days | 35 Days |
Enterprise Value | $31.32B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
FUBO trades at $9.03, down 2.38% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M in 2025, representing a significant turnaround from previous losses. Recent developments include new sports streaming agreements with NHL teams and expanded partnerships with The Athletic, positioning the company for continued subscriber growth.
FUBO presents a compelling turnaround story with deep valuation discounts (P/E 2.43, P/S 0.19) and analyst consensus target of $63.38 suggesting 600%+ upside. However, risks include persistent cash flow challenges, high debt levels, and intense streaming competition. The Disney partnership and sports content expansion provide catalysts, but execution risk remains elevated given the company's history of losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
